Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.
de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, Roessler D, Ben Khaled N, Jeschke M, Ludwig JM, Marquardt JU, Weinmann A, Pinter M, Lange CM, Vogel A, Saborowski A. de Castro T, et al. Among authors: scheiner b. Ther Adv Med Oncol. 2022 Feb 26;14:17588359221080298. doi: 10.1177/17588359221080298. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35251317 Free PMC article.
Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.
Stift J, Semmler G, Walzel C, Mandorfer M, Schwarzer R, Schwabl P, Paternostro R, Scheiner B, Wöran K, Pinter M, Stättermayer AF, Trauner M, Peck-Radosavljevic M, Ferlitsch A, Reiberger T. Stift J, et al. Among authors: scheiner b. Dig Liver Dis. 2019 Aug;51(8):1144-1151. doi: 10.1016/j.dld.2019.01.020. Epub 2019 Feb 12. Dig Liver Dis. 2019. PMID: 30862438
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.
Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M. Scheiner B, et al. Aliment Pharmacol Ther. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245. Epub 2019 Apr 12. Aliment Pharmacol Ther. 2019. PMID: 30980420 Free PMC article.
Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.
Semmler G, Simbrunner B, Scheiner B, Schwabl P, Paternostro R, Bucsics T, Stättermayer AF, Bauer D, Pinter M, Ferenci P, Trauner M, Mandorfer M, Reiberger T. Semmler G, et al. Among authors: scheiner b. J Gastroenterol Hepatol. 2019 Dec;34(12):2164-2172. doi: 10.1111/jgh.14700. Epub 2019 Jun 14. J Gastroenterol Hepatol. 2019. PMID: 31062417 Free PMC article.
Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.
Semmler G, Stift J, Scheiner B, Wöran K, Schwabl P, Paternostro R, Bucsics T, Stättermayer AF, Pinter M, Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Semmler G, et al. Among authors: scheiner b. Dig Dis Sci. 2019 Dec;64(12):3642-3651. doi: 10.1007/s10620-019-05702-7. Epub 2019 Jun 17. Dig Dis Sci. 2019. PMID: 31209721 Free PMC article.
Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.
Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M. Scheiner B, et al. United European Gastroenterol J. 2019 Jul;7(6):850-858. doi: 10.1177/2050640619840199. Epub 2019 Mar 21. United European Gastroenterol J. 2019. PMID: 31316789 Free PMC article.
167 results